danicamtiv
Small moleculeexperimental
Clinical trial activity
8 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
1
Phase 4
0
Earliest trial started Jan 16, 2017 (NCT03062956)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(S(=O)(=O)[C@@](C)(F)C2CCN(C(=O)Nc3ccon3)CC2)c(C(F)F)n1- Mol. weight
- 435.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594304 ↗
Also known as
- myk-491
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07210723 | Phase 2/Phase 3 (Phase 3) | Nov 30, 2025 | Kardigan, Inc. |
| NCT06027437 | Phase 1 | Sep 5, 2023 | Bristol-Myers Squibb |
| NCT05952089 | Phase 1 | Aug 17, 2023 | Bristol-Myers Squibb |
| NCT05806359 | Phase 1 | Mar 31, 2023 | Bristol-Myers Squibb |
| NCT05162222 | Phase 1 | Dec 15, 2021 | Bristol-Myers Squibb |
| NCT04572893 | Phase 2 | Aug 19, 2020 | MyoKardia, Inc. |
| NCT03447990 | Phase 1 | Feb 6, 2018 | MyoKardia, Inc. |
| NCT03062956 | Phase 1 | Jan 16, 2017 | MyoKardia, Inc., Nucleus Network Ltd |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 1 | 2021 |
| MyoKardia, Inc. | For profit | 3 | 3 | 2 | 2017 |
| Kardigan, Inc. | For profit | 1 | 1 | 1 | 2025 |
| Nucleus Network Ltd | For profit | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1